Page last updated: 2024-12-07
km 200
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
Grotan BK: contains 1,3,5-tris(hydroxyethyl)hexahydrotriazine; releases formaldehyde; bactericidal agent in coolant liquids; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 104556 |
| CHEMBL ID | 3561636 |
| SCHEMBL ID | 125784 |
| MeSH ID | M0058448 |
Synonyms (90)
| Synonym |
|---|
| 4719-04-4 |
| hexahydro-1,5-tris(hydroxyethyl)triazine |
| 1,5-tris(2-hydroxyethyl)hexahydro-s-triazine |
| onyxide 200 |
| grotan bk |
| grotan hd |
| grotan |
| nsc-516387 |
| hexahydro-1,5-tris(2-hydroxyethyl)-s-triazine |
| s-triazine-1,5(2h,4h,6h)-triethanol |
| hexahydro-1,5-tris(2-hydroxypropyl)-s-triazine |
| rancidity control agent |
| 1,5-tris(2-hydroxyethyl)hexahydro-1,3,5-triazine |
| 1,5-triazine-1,3,5(2h,4h,6h)-triethanol |
| kalpur te |
| grotan b |
| nsc516387 |
| hexahydro-1,5-tris(2-hydroxyethyl)triazine |
| 1,3,5-tris(2-hydroxyethyl)hexahydro-1,3,5-triazine |
| roksol t 1-7 |
| km 200 (alcohol) |
| brn 0124982 |
| 1,3,5-tris(2-hydroxyethyl)hexahydro-s-triazine |
| actane |
| ottaform 204 |
| 1,3,5-tris(hydroxy-ethyl)s-hexahydrotriazine |
| triazinetriethanol |
| hexahydro-1,3,5-triazine-1,3,5-triethanol |
| 2,2',2''-(hexahydro-1,3,5-triazine-1,3,5-triyl)triethanol |
| hexahydro-1,3,5-tris(2-hydroxyethyl)-s-triazine |
| hexahydro-1,3,5-tris(hydroxyethyl)triazine |
| ccris 6246 |
| eta 75 |
| s-triazine-1,3,5(2h,4h,6h)-triethanol |
| caswell no. 481c |
| busan 1060 |
| einecs 225-208-0 |
| nsc 516387 |
| epa pesticide chemical code 083301 |
| 2,2',2''-(1,3,5-triazinane-1,3,5-triyl)triethanol |
| 1,3,5-triazine-1,3,5(2h,4h,6h)-triethanol |
| bactraclean |
| triadine 3 |
| hexahydro-1,3,5-tri(2-hydroxyethyl)-s-triazine |
| 1,3,5-tris(2-hydroxyethyl)-1,3,5-triazacyclohexane |
| n,n',n''-tris(2-hydroxyethyl)hexahydro-s-triazine |
| busan 1506 |
| s-triazine-1,3,5-triethanol |
| permachem ob 2 |
| protectol ht |
| surcide p |
| surcide d |
| bioban gk |
| cobate c |
| nipacide bk |
| acticide gr |
| 2-[3,5-bis(2-hydroxyethyl)-1,3,5-triazinan-1-yl]ethanol |
| hexahydro-1,3,5-tris(hydroxyethyl)-s-triazine |
| ec 225-208-0 |
| ou2jeb22ie , |
| km-200 |
| unii-ou2jeb22ie |
| 4-26-00-00010 (beilstein handbook reference) |
| km 200 |
| 1,3,5-trihydroxyethylhexahydrotriazine |
| FT-0675394 |
| SCHEMBL125784 |
| 1,3,5-tris-hydroxyethyl perhydro-s-triazine |
| 1,3,5-tris(2-hydroxyethyl)perhydro-s-triazine |
| 1,3,5-tris(2-hydroxyethyl)perhydro-s-tria-zine |
| tris(n-hydroxyethyl) hexahydrotriazine |
| tris(n-hydroxyethyl) hexahydrotriazine [inci] |
| eta-75 |
| tris(.beta.-hydroxyethyl)hexahydro-s-triazine |
| AKOS024462548 |
| dtxcid405394 |
| tox21_303727 |
| cas-4719-04-4 |
| NCGC00357283-01 |
| dtxsid7025394 , |
| hexahydro-1,3,5-tris(2-hydroxyethyl)triazine |
| tris-hydroxyethyl-hexahydro-s-triazine |
| miliden x-2 |
| CHEMBL3561636 |
| appolo-207 |
| mfcd01678788 |
| Q27285845 |
| CS-W018942 |
| c9h21n3o3 |
| PD056846 |
Research Excerpts
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| " In addition, as a positive control, benzidine at a total dosage of 409." | ( An evaluation of the mutagenicity of the cutting oil preservative Grotan BK. Palmer, AK; Richardson, JC; Urwin, C, 1976) | 0.26 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (4)
Potency Measurements
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 27.3060 | 0.0060 | 38.0041 | 19,952.5996 | AID1159521 |
| GLI family zinc finger 3 | Homo sapiens (human) | Potency | 0.2434 | 0.0007 | 14.5928 | 83.7951 | AID1259369 |
| AR protein | Homo sapiens (human) | Potency | 43.2771 | 0.0002 | 21.2231 | 8,912.5098 | AID1259243 |
| retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 68.5896 | 0.0030 | 41.6115 | 22,387.1992 | AID1159552; AID1159555 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Research
Studies (12)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 6 (50.00) | 18.7374 |
| 1990's | 1 (8.33) | 18.2507 |
| 2000's | 4 (33.33) | 29.6817 |
| 2010's | 1 (8.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 67.75
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (67.75) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 2 (16.67%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 10 (83.33%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||